NCT04573322View on ClinicalTrials.gov

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 10, 2020

Primary Completion Date

March 17, 2021

Study Completion Date

April 29, 2021

Conditions
SARS-CoV-2 (Covid19)
Interventions
DRUG

Trans Sodium Crocetinate

TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days

DRUG

Normal saline

Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days

Trial Locations (1)

021105

National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest

Sponsors
All Listed Sponsors
lead

Diffusion Pharmaceuticals Inc

INDUSTRY